Updated hourlyHourly refreshSun, Oct 25, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
New York, Aug. 21, 2026 -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.
Aug 21 · 16:20·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(August 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by...
Aug 21 · 16:15·Newsfile
Healthcare · Biotech & pharma
MIAMI LAKES, Fla., August 21, 2026--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.
Aug 21 · 15:33·Business Wire
Finance · Biotech & pharma
SAN DIEGO, Aug. 21, 2026 -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until...
Aug 21 · 15:15·PR Newswire
Healthcare · Biotech & pharma
U.S. market to reach USD 156.90M and Europe USD 96.02M by 2035, driven by pharma R&D, biomarker development and multiplexed imaging.
U.S. market to reach USD 156.90M and Europe USD 96.02M by 2035, driven by pharma R&D, biomarker development and multiplexed imaging.
Aug 21 · 15:00·GlobeNewswire
Healthcare · Biotech & pharma
SHANGHAI, Aug. 21, 2026 -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed...
Aug 21 · 12:08·PR Newswire
Finance · Healthcare
BRANFORD, Conn., Aug. 21, 2026 -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced...
Aug 21 · 12:00·PR Newswire
Finance · Biotech & pharma
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.
Aug 21 · 12:00·GlobeNewswire
Finance · Healthcare
SAN DIEGO, Aug. 21, 2026 -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia.
Aug 21 · 12:00·GlobeNewswire
Healthcare · Biotech & pharma
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)
Aug 21 · 12:00·GlobeNewswire
Finance · Healthcare
SAN DIEGO, August 21, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing e
Aug 21 · 12:00·Business Wire
AI · Education
RUTHERFORD, N.J. & LA JOLLA, Calif., August 21, 2026--Lōkahi and UGA launch an ai² Futures Lab initiative focused on sourcing and evaluating underdeveloped therapeutic assets for future growth.
Aug 21 · 12:00·Business Wire